Kyocera | August 13, 2021
Kyocera, a leader in ceramics-based medical devices, will unveil its “CAM” (ceramic additive manufacturing) customized 3D printing service for cost-effective prototypes of new medical device designs at the MD&M West Medical Expo in Anaheim, Calif., August 10-12, the world’s largest annual convention for medical product designers and manufacturers. Kyocera’s new service utilizes both zirconia and alumina materials in a wide variety of shapes, a size range of 200 x 105 x 40mm and wall thickness of 0.25-10mm. The simple 3-step process rapid-produces samples: simply send a 3D CAD file, complete a consultation the next day and then prototypes are created in 1-2 weeks*. Additionally, Kyocera will also be showcasing its wide range of ceramics-based medical technologies during the expo.
Rapid Custom Samples with CAM
Incorporating 60+ years of product development expertise, Kyocera’s engineers consult on each new project and devise the most cost-effective method for a 3D printed prototype of new medical device designs. With that consultation and 3D printing using zirconia and alumina, Kyocera is able to produce virtually any kind of customized prototype in 1-2 weeks. Kyocera’s ceramics offer scratch resistance, higher rigidity, temperature resistance, longer lifetime, high-voltage insulation, lighter weight, and superior thermal management, providing an overall lower cost of ownership.
According to MD&M West, the global medical device manufacturing market is expected to exceed $200 billion by 2025, largely due to an aging population, chronic disease and advancements in technology to help various conditions. Kyocera continues to use its unique ceramic “superhero” materials to help advance medical technologies. The Company’s Fine Ceramics provide a highly durable, long-lasting, non-reactive material that can be found in solutions for genetic sequencing; microfluidic tools; X-ray, PET, MRI and CT scan machines; pacemakers and cardiac monitors; neuromodulation devices; surgical tools; drug testing devices and orthopedic joint replacement systems. Information on these innovative ceramic medical solutions and more will be on display at Kyocera’s booth throughout the show.
Kyocera Corporation (TOKYO: 6971), the parent and global headquarters of the Kyocera Group, was founded in 1959 as a producer of fine ceramics (also known as “advanced ceramics”). By combining these engineered materials with metals and integrating them with other technologies, Kyocera has become a leading supplier of industrial and automotive components, semiconductor packages, electronic devices, smart energy systems, printers, copiers, and mobile phones. During the year ended March 31, 2021, the company’s consolidated sales revenue totaled 1.5 trillion yen (approx. US$13.8 billion). Kyocera is ranked #603 on Forbes magazine’s 2021 “Global 2000” list of the world’s largest publicly traded companies, and appears on The Wall Street Journal’s latest list of “The World’s 100 Most Sustainably Managed Companies.”
prnewswire | December 21, 2020
Else Provides U.S. Retail Launch and Production Update Else Provides U.S. Retail Launch and Production Update
The Company dispatched its Else Plant-Based Complete Nutrition for Toddlers in mid-August of this current year on elsenutrition.com, trailed by a dispatch on Amazon.com in late September, where it turned into the #1 on Amazon's top rated up and coming deliveries in Baby and Toddler Formula classification.
The Company is glad to refresh that Customer input is overwhelmingly sure with elevated level of fulfillment with item quality and impact on kids. The company has sloped up its creation intends to satisfy need in 2021.
With the assistance of a few retail handles, Else has just recorded its item with five (5) common food retail chains, with a sum of 380 stores. In November, Else got the principal buy orders from KeHE Distributors, and transported item to the initial five dissemination habitats initiated by KeHE for Else across the U.S., expecting to have item on retail retires for the coming Christmas season.
Item was dispatched to KeHE's Distribution Centers , and will be delivered to retail chains during the following 90 days to accommodate request.
The company commenced on its fourth commercial assembling run since July this year, and keeps on building stock to support the on the web and retail development in the U.S. market.
"We continue to refine our manufacturing process to consistently produce high quality, easily dissolved and tasty product," said Ms. Hamutal Yitzhak, CEO and Co-Founder of Else. "Having a consistent, high quality, efficient and scalable manufacturing process is a critical pillar of our business and future success," she added.
About Else Nutrition Holdings Inc.
Else Nutrition GH Ltd. is an Israel-based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the "2017 Best Health and Diet Solutions" award at the Global Food Innovation Summit in Milan. The holding company, Else Nutrition Holdings Inc., is a publicly traded company, listed as TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QX board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else's Executives includes leaders hailing from leading infant nutrition companies. Many of Else advisory board members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies, and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children's Hospital, Pediatrics at Harvard Medical School, USA, Tel Aviv University, Schneider Children's Medical Center of Israel, Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium.
Pfizer | October 19, 2020
US pharmaceutical giant Pfizer has begun manufacturing hundreds of thousands of doses of its COVID-19 vaccine ahead of its expected approval next month. The UK’s Daily Mail on Sunday published video showing a manufacturing plant in Puurs, Belgium with thousands of doses of the vaccine coming off the production line.
Pfizer said last week it expects to file for emergency use authorization for its COVID-19 vaccine in late November, around two weeks after the November 3 US presidential election. The company said it hopes to move ahead with the vaccine after safety data is available in the third week of November.
The company has said it hopes to make 100 million doses available this year and a massive 1,3 billion available in 2021. Each recipient will need two doses.
“It was great to see the first vial coming off the manufacturing line,” Pfizer UK head Ben Osborn told the Daily Mail. “It just brought a tremendous smile to my face to see all of this work actually result in a product.”
In July the US announced it will pay Pfizer nearly $2 billion for a December delivery of 100 million doses of a COVID-19 vaccine the pharmaceutical company is developing. The US could buy another 500 million doses under the agreement.
The agreement is part of US President Donald Trump’s Operation Warp Speed vaccine program, under which multiple COVID-19 vaccines are being developed simultaneously. The program aims to deliver 300 million doses of a safe and effective COVID-19 vaccine by January 2021.
Under the initiative, the government will speed development and buy vaccines — before they are deemed safe and effective — so that the medication can be in hand and quickly distributed once the FDA approves or authorizes its emergency use after clinical trials.
The Pfizer announcement last week means the United States could have two vaccines ready by the end of the year, with Massachusetts biotech firm Moderna aiming for November 25 to seek authorization. The Food and Drug Administration (FDA), which authorizes pharmaceuticals for distribution in the US — asked vaccine developers last week to spend two months monitoring for serious side effects after the second dose is given to trial participants.
The FDA will require the vaccine to prove effective and safe, while Pfizer will have to demonstrate it is capable of producing large scale production. Pfizer and Modern, both funded by the US government, launched Phase 3 of their clinical trials at the end of July, and both have started production of doses.